BRD4 and nevus comedonicus syndrome: However, further experiments and many more investigations are needed to confirm this first data set and to transfer it to other NC cancer cell lines, including those that do not carry BRD4 as a fusion partner, which may uncover additional co-actors and novel therapeutic targets.